SCHEMBL31342186

SCHEMBL31342186

COc1cc(C2CCN(c3cccc4c3n(C)c(=O)n4C3CCC(=O)NC3=O)CC2)ccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 11/20 0.48
▸ CRBN Q96SW2 11/20 0.48
▸ ADAM17 P78536 1/20 0.39
▸ ADAMTS5 Q9UNA0 1/20 0.39
▸ IKZF2 Q9UKS7 4/20 0.36
▸ HTR1A P08908 1/20 0.34
▸ HTR1D P28221 1/20 0.34
▸ HTR1B P28222 1/20 0.34
▸ HTR2A P28223 1/20 0.34
▸ HTR2C P28335 1/20 0.34
▸ HTR1E P28566 1/20 0.34
▸ HTR7 P34969 1/20 0.34
▸ HTR2B P41595 1/20 0.34
▸ HTR3A P46098 1/20 0.34
▸ HTR5A P47898 1/20 0.34
▸ IKZF1 Q13422 2/20 0.34
▸ IKZF3 Q9UKT9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31342609 0.90 CRBN (0.49) DDB1CRBNIKZF2IKZF1
SCHEMBL31342153 0.87 DDB1 (0.53) DDB1CRBNIKZF3
SCHEMBL31341846 0.87 CRBN (0.46) DDB1CRBNIKZF2IKZF1
SCHEMBL31342161 0.86 CRBN (0.46) DDB1CRBNIKZF2IKZF1IKZF3
SCHEMBL31342647 0.85 DDB1 (0.43) DDB1CRBNIKZF2IKZF1
SCHEMBL31342024 0.81 ADAM17 (0.38) DDB1CRBNADAM17ADAMTS5IKZF2
SCHEMBL31342138 0.80 CRBN (0.47) DDB1CRBNIKZF2IKZF1IKZF3
SCHEMBL23728483 0.80 DDB1 (0.60) DDB1CRBNIKZF3
SCHEMBL23728576 0.79 DDB1 (0.62) DDB1CRBNIKZF3
SCHEMBL24778533 0.79 DDB1 (0.54) DDB1CRBNIKZF3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
WO-2025049820-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2025-03-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF STAT6, NCOR2, NCOR1 DDB1 3932/4885CRBN 207/4885ADAM17 4737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback